Cyclis Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Normally during the cell cycle, molecular signaling checkpoints prevent cell division in the event of chromosomal shuffling or DNA damage. Cyclis Pharmaceuticals is developing cancer drugs that turn on the deactivated cellular surveillance system, leading to apoptosis and cell death.